Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 October 2024 | Story Leonie Bolleurs | Photo Supplied
Thandi Mazibuko
Thandi Mazibuko, with her presentation: LED there be light, was the overall institutional winner in the PhD category and the runner-up in the national competition of this year’s 3MT competition.

The Centre for Graduate Support (CGS) recently (11 October 2024) hosted the annual institutional Three-Minute Thesis Competition (3MT), which was followed by the national competition (25 October). This year, the nationals took place on the UFS Bloemfontein Campus. According to Tshepiso Mokoena, responsible for Research Capacity Development in CGS, the participating master’s and PhD students gave well-prepared presentations. The competition aims to equip postgraduate students with valuable communication and presentation skills.

She says that postgraduate students are encouraged to do research that will benefit the community. “To do this, students should be able to communicate and present their research to a non-specialist audience. The 3MT competition trains and equips them with skills that they will use in their community and workplace,” she noted.

Overall PhD winner

The overall winner in the PhD category of the UFS competition was Thandi Mazibuko with her presentation: LED there be light. Thandi was also announced as the first runner-up at the national competition.

Growing up in Qwaqwa, Thandi’s passion for mathematics and the natural sciences led her to pursue a BSc Physics degree at the UFS in 2013, followed by an honours at the UFS. She then completed her MSc at the University of the Western Cape and worked as a science engagement intern at iThemba LABS in Cape Town, which inspired her to start a YouTube channel with more than 4 800 subscribers, called Thandisayensi. On this channel she uploads Physical Sciences videos for learners in grades 10-12.

Thandi states that she loves learning and being in learning environments; in 2022, she registered for a PhD in Solid State Physics under the supervision of Prof Hendrik Swart and Prof David Motaung.

Her research focuses on synthesising a phosphor material capable of emitting red, green, and blue light, which, when combined, creates the perception of white light. Thandi compared the research process to cooking, explaining how the preparation of phosphors resembles food preparation. She believes that relatable language, analogies, and storytelling are important tools in science communication.

Thandi says that this competition was a valuable platform to improve her science communication skills. “It is an interesting challenge to explain your work in 180 seconds to an audience with different backgrounds,” she said, adding that she is excited to represent the UFS at the national competition.

The other winners

Each department hosts its own 3MT competition, and the winners and runners-up in both the master’s and PhD categories then represent their faculty in the institutional competition.

The master’s category winners from other faculties were:

  • Faculty of Economic and Management Sciences: Evodia Mohoanyane with Does SI/tutoring work and what about it works? Evodia was also the overall winner in the institutional competition in the master’s category.
  • The Humanities: Yonwaba Matshobotiyana with Of Speaking and Visibility: Black Women Poets' Voices in South Africa
  • Health Sciences: Viwe Fokazi with Establishing a novel 3D doxorubicin-resistant triple-negative breast cancer spheroid model

In the PhD category, the winners were:

  • Economic and Management Sciences: Chrizaan Grobbelaar with The use of gamification to enhance retirement preparedness of millennials
  • The Humanities: Sheree Pretorius with The Psychometric Properties of the Prison Adjustment Questionnaire (PAQ) among South African Male Incarcerated Offenders

With Thandi, first runner-up of the institutional competition, Chrizaan, participated in the national 3MT competition. Universities such as the Nelson Mandela University, UNISA, University of KwaZulu-Natal, University of the Western Cape, University of Johannesburg, and the Central University of Technology were also present. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept